ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMSpese di vendita, generali e amministrative2.42 B2.47 B2.75 B2.74 B3.13 B2.93 B11.56 BRicerca e sviluppo3.21 B4.31 B3.49 B4.12 B4.33 B4.09 B16.04 BReddito operativo4.6 B3.7 B6.87 B7.37 B7.89 B8.91 B31.03 BProventi non operativi, Totale-110.1 M-239 M-90.6 M-133.1 M-108.3 M-65 M-397 MOneri finanziari, al netto degli interessi capitalizzati224.7 M243.7 M249 M179.6 M222.7 M——Proventi non operativi, esclusi gli oneri finanziari-84.6 M-235.5 M10.4 M46.3 M-108.3 M-65 M-116.6 MEntrate/uscite straordinarie-25.5 M-3.5 M-101 M-179.4 M———Utile al lordo delle imposte5.04 B3.46 B6.78 B7.23 B8.27 B8.85 B31.13 BQuota di utile———————Imposte628.9 M696.8 M1.12 B1.65 B1.63 B1.45 B5.85 BInteressi di minoranza———————Altri proventi/oneri al netto delle imposte———————Utile netto al lordo delle attività cessate4.41 B2.76 B5.66 B5.58 B6.64 B7.4 B25.28 BAttività cessate———————Utile netto4.41 B2.76 B5.66 B5.58 B6.64 B7.4 B25.28 BRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari4.41 B2.76 B5.66 B5.58 B6.64 B7.4 B25.28 BUtile base per azione (EPS base)4.93.076.36.227.418.2728.2Utile diluito per azione (EPS diluito)4.883.066.296.217.398.2628.15Numero medio di azioni ordinarie in circolazione900.61 M898.7 M897.9 M896.9 M897.3 M894.5 M—Azioni diluite in circolazione904.06 M900.6 M899.8 M898.8 M899.3 M895.9 M—EBITDA5.08 B4.16 B7.35 B7.84 B8.47 B9.42 B33.08 BEBIT4.6 B3.7 B6.87 B7.37 B7.89 B8.91 B31.03 BCosto del fatturato2.4 B2.22 B2.45 B3.01 B3.37 B3.58 B12.4 BAltri costi del venduto———————Ammortamento e svalutazione (liquidità)484.8 M462.8 M478.3 M470 M585.7 M509 M2.04 B
Eli Lilly and Company Common Stock
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.
The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes.